Influence of pregnancy on the pharmacokinetic behaviour and the transplacental transfer of the piperacillin-tazobactam combination

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 76, Issue 1, 1998, Pages 21-27

  Bourget, Philippe ^a   Sertin, Antony ^b   Lesne Hulin, Anne ^b   Fernandez, Hervé ^c   Ville, Yves ^c   Van Peborgh, Pascal ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

HPLC; Pharmacokinetics; Piperacillin tazobactam combination; Pregnancy; Therapeutic monitoring; Trans placental transfer

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ADULT; AMNION FLUID; ARTICLE; CHORIOAMNIONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE; DRUG MONITORING; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; FETUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MATERNAL BLOOD; NORMAL HUMAN; PLACENTA; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; STAPHYLOCOCCUS; STEADY STATE; ULTRAVIOLET SPECTROPHOTOMETRY; UMBILICAL CORD BLOOD; URINARY EXCRETION; URINARY TRACT INFECTION;

EID: 0031962694     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(97)00150-4     Document Type: Article

References (27)

1. [1] Schwarz RH. Considerations of antibiotic therapy during pregnancy. Obstet Gynecol 1981;58:S95-99.
2. [2] Chow AW, Jewesson PJ. Pharmacokinetics and safety of anti-microbial agents during pregnancy. Rev Infect Dis 1985;7:287-313.
3. [3] Knott C, Reynolds F. Therapeutic drug monitoring in pregnancy. Clin Pharmacokinet 1990;19:425-33.
4. [4] Bawdon RE. Anti-infective chemotherapy in obstetrics and gynecology. In: Charles D, editor. Obstetrics and perinatal infections. St. Louis, 1993.
5. [5] Bourget P, Roulot C, Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet 1995;28:161-80.
6. [6] Cullmann W. Interaction of β-lactamase inhibitors with various β-lactamases. Chemotherapy 1990;36:200-8.
7. [7] Moellering RC. Meeting the challenges of β-lactamases. J Antimicrob Chemother 1993;31:1-8.
8. [8] Bryson HM, Brogden RN. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47(3):506-35.
9. [9] Bourget P, Lesne-Hulin A, Le Reveillé R, Le Bever H, Carsin H. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996;40:139-45.
10. [10] Meulemans A, Mohler J, Decazes JM. Determination of piperacillin in plasma and cerebrospinal fluid by high-performance liquid chromatography. J Chromatogr 1983;6:575-80.
11. [11] Marunaka T, Maniwa M, Matsushima E. High-performance liquid chromatographic determination of a new β-lactamase inhibitor and its metabolite in combination therapy with piperacillin in biological materials. J Chromatogr 1988;431:87-101.
12. [12] Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea and Febiger, 1995.
13. [13] Bourget P, Delouis JM. Methods for assessment of area under the curve in pharmacokinetic analysis. Therapie 1993;48:1-5.
14. [14] Yamaoka K, Nakagawa W, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:547-80.
15. [15] Benet LZ, Galeazzi RL. Non-compartmental determination of the steady state volume of distribution. J Pharm Sci 1979;68:1071-3.
16. [16] Colburn WA. Estimating the accumulation of drugs. J Pharm Sci 1983;72:833-4.
17. [17] Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993;31:S39-60.
18. [18] Cheung WK, Greene DS, Kuye O. Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration. In: 6th Mediterranean Congress of Chemotherapy, 1988, 22-27 May, Abstract 159.
19. [19] Cheung WK, Greene DS, Kuye O. Pharmacokinetics of YTR830H and piperacillin in healthy human subjects. In: 6th Mediterranean Congress of Chemotherapy, 1988, 22-27 May, Abstract 158.
20. [20] Heikkila A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother 1991;28:419-23.
21. [21] Voigt R, Schröder S, Peiker G. Pharmacokinetic studies of azlocillin and piperacillin during late pregnancy. Chemotherapy 1985;31:417-24.
22. [22] Tjandramaga TB, Mullie A, Verbesselt R. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978;14:829-37.
23. [23] Bergan T, Williams JD. Dose dependency of piperacillin pharmacokinetics. Chemotherapy 1982;28:153-9.
24. [24] Boobis A, Lewis P. Drugs in pregnancy: altered pharmacokinetics. Br J Hosp Med 1982;12:566-73.
25. [25] Antibiogram Committee of the French Society for Microbiology. Statement. Pathol Biol 1996;44:1-8.
26. [26] Hedstrom S, Martens MG. Antibiotics in pregnancy. Clin Obstet Gynecol 1993;36:886-92.
27. [27] Romero R, Quintero R, Oyarzun E. Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. Am J Obstet Gynecol 1988;159:661-6.